M&A Deal Summary |
|
|---|---|
| Date | 2017-12-07 |
| Target | Cell Design Labs |
| Sector | Life Science |
| Buyer(s) | Kite Pharma |
| Deal Type | Add-on Acquisition |
| Deal Value | 567M USD |
| Advisor(s) | Citi (Financial) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2009 |
| Sector | Life Science |
| Employees | 184 |
| Revenue | 22M USD (2016) |
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT designed to restore the immune system's ability to recognize and eradicate tumors. Kite Pharma was formed in 2009 and is based in Santa Monica, California.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 4 |
| Sector: Life Science M&A | 2 of 4 |
| Type: Add-on Acquisition M&A Deals | 2 of 3 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 3 |
| Year: 2017 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-03-17 |
T-Cell Factory B.V.
Netherlands T-Cell Factory B.V. develops tumor-specific TCRs for broad application in cancer treatment based on its proprietary TCR-GENErator™ platform. |
Buy | €20M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-07-19 |
Kite Pharma - Neoantigen TCR Cell Therapy R&D Platform & Manufacturing Facility
Gaithersburg, Maryland, United States Kite Pharma's Neoantigen TCR Cell Therapy R&D Platform & Manufacturing Facility provides production capacity to support clinical trials. |
Sell | - |
